Fusion Pharmaceuticals Inc. (FUSN) Tops Q3 EPS by 15c

Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) reported Q3 EPS of ($0.25), $0.15 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $2.01 million versus the consensus estimate of $86 thousand.

For earnings history and earnings-related data on Fusion Pharmaceuticals Inc. (FUSN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c